In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Natural peptide Thymosin beta-4 (human) | Synthetic analog Cibinetide (ARA-290) | |
|---|---|---|---|
| Identity | |||
| Kind | Natural peptide | Synthetic analog | |
| Area | Recovery and repair | Recovery and repair | |
| Evidence | |||
| Amount of evidence | 1,449 (plus 953 on natural levels, listed separately) | 366 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 12 (8 in people) | 10 (4 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 13 · 1 active2 more mention it but do not test it | 4 | |
Shared outcomes
From the regulatory data of each peptide.
Its most advanced trial is in phase 3. The FDA, the EMA and the other sources we use show no approval (as of 8 Oct 2026).
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Thymosin beta-4 (human) | Cibinetide (ARA-290) |
|---|---|---|
| Receptor activity and mechanismWhole body | 310292792 | 21 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
Its most advanced trial is in phase 2. The FDA, the EMA and the other sources we use show no approval (as of 9 Oct 2026).
| Inflammation markersWhole body | 1447668 | 926824 |
|---|
| NeuroprotectionNervous system and cognition | 1437964 | 397248 |
|---|
| Wound healingWhole body | 12156650 | 271710 |
|---|
| Immune responseImmune and inflammation | 861472 | 261169 |
|---|
| Heart functionCardiovascular | 7225515 | 44 |
|---|
| Liver fat and liver functionLiver | 794237 | 11 |
|---|
| Bone and jointMusculoskeletal | 531142 | 651 |
|---|
| Cell viability and deathWhole body | 4747 | 66 |
|---|
| Adverse eventsWhole body | 981 | 936 |
|---|
| PainNervous system and cognition | 523 | 20614 |
|---|
| Kidney functionKidney and urinary | 14131 | 29218 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Cibinetide (ARA-290) differs from Erythropoietin (human) at 7 positions.
What is different
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Thymosin beta-4 (human) | Cibinetide (ARA-290) |
|---|---|---|
| PainNervous system and cognitionCompared as: value in the arm that got the peptide, in points | No comparable result 2 randomized-trial results measure it in another way or another unit. | −11.5 points SFNSL score change · ARA 290 Placebo: −2.9 points Dose studied: 2 mg three times weekly4 weeksn = 222012 |
| Exercise and physical functionNervous system and cognitionCompared as: value in the arm that got the peptide, in points | No randomized trial result 1 result from other study designs. | −14.6 points SF-36 physical functioning change · ARA 290 Dose studied: 2 mg three times weekly4 weeksn = 122012 |
No comparable result
2 randomized-trial results measure it in another way or another unit.
−11.5 points
SFNSL score change · ARA 290
Placebo: −2.9 points
Dose studied: 2 mg three times weekly4 weeksn = 222012
No randomized trial result
1 result from other study designs.
−14.6 points
SF-36 physical functioning change · ARA 290
Dose studied: 2 mg three times weekly4 weeksn = 122012
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 13 trials, ranked by phase, then posted results and enrollment: 2 completed · 1 stopped early · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
ReGenTree, LLC700 participants24 May 2019 to 7 Oct 2021
Dry Eye Syndromes · Dry Eye
ReGenTree, LLC601 participantsNov 2016 to Mar 2018
Dry Eye Syndrome
ReGenTree, LLC18 participants17 Sept 2015 to 9 Mar 2020
Neurotrophic Keratopathy
2 more mention it but do not test it. They only measure it or name it in their text.
Top 3 of 4 trials, ranked by phase, then posted results and enrollment: 2 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)
Araim Pharmaceuticals, Inc.64 participantsJan 2014 to Feb 2015
Neuropathy of Sarcoidosis
Leiden University Medical Center36 participantsFeb 2012 to Feb 2014
Depression
Claes-Göran Östenson24 participantsOct 2013 to est. Dec 2015
Diabetes Type 2 · Impaired Glucose Tolerance · Impaired Fasting Glucose